According to TipRanks, Akyol is a 3-star analyst with an average return of 1.8% and a 57.14% success rate. Akyol covers the Industrial Goods sector, focusing on stocks such as Dcp Midstream Partners, Enterprise Products Partners, and Global Partners.
In addition to Stifel Nicolaus, Plains All American also received a Buy from Mizuho Securities’s Gabe Moreen in a report issued on August 8. However, on August 4, UBS maintained a Hold rating on Plains All American (NASDAQ: PAA).
PAA market cap is currently $8.19B and has a P/E ratio of 14.20.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PAA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Plains All American Pipeline LP engages in the provision of transportation, storage, terminalling and marketing of crude oil, refined products and other natural gas-related petroleum products. It operates through the following business segments: Transportation, Facilities, and Supply and Logistics. The Transportation segments consist of fee-based activities associated with transporting crude oil and refined products on pipelines, gathering systems, trucks and barges. The Facilities segment includes fee-based activities associated with providing storage, terminalling and throughput services for crude oil, refined products, and natural gas, as well LPG fractionation and isomerization services. The Supply and Logistics segment is engaged in the sale of gathered and bulk-purchased crude oil and natural gas liquids volumes. The company was founded in 1998 and is headquartered in Houston, TX.
Read More on PAA:
- Venus Concept (VERO) Gets a Buy from Maxim Group
- Reed’s (REED) Receives a Buy from Maxim Group
- Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
- Citius Pharmaceuticals (CTXR) Receives a Buy from Maxim Group
- Maxim Group Keeps Their Hold Rating on Omeros (OMER)